Appointment Reinforces Brainsway’s U.S. Presence
Har Hahozvim, Israel, September 10, 2015 - Brainsway® Ltd. (TASE: BRIN), a leading company developing revolutionary brain disorder treatments, announced that Joseph Perekupka has joined the company as Vice President of Sales Operations, North America.
“We are thrilled to welcome Joseph Perekupka to Brainsway,” said Dr. Guy Ezekiel, Brainsway's President & CEO. “Joseph brings a wealth of expertise and accomplishments in the medical technology industry that will be invaluable to us in executing our plan of building up our U.S. market presence.”
Perekupka will manage Brainsway's U.S. operations from the company's headquarters in Philadelphia. In this role, he will lead Brainsway's sales operations in the United States and Canada, executing the company’s penetration program in those areas.
“Brainsway is performing incredibly innovative and important work in the North American market, increasing the reach of the Deep TMS depression treatment, and I am excited to take part in the company’s expansion,” said Perekupka. “I am fortunate to have led activities related to groundbreaking medical technologies, and this role at Brainsway offers a wonderful opportunity for applying my experience.”
Throughout his 20-year leadership career, Perekupka served as an executive in a variety of companies, including Biotronik Inc., a company specializing in advanced cardiology devices, St. Jude Medical Inc., a cardiovascular manufacturing company, and Forest Laboratories, a company focusing on the manufacturing of pharmaceutical products. In addition, he held senior management positions at Bristol-Meyers Squibb. Perekupka earned a B.A. in Economics from Pennsylvania State University and an MBA in Management and Finance from Fordham University.
Brainsway is a leading company dedicated to developing breakthrough brain disorder treatment. Brainsway's Deep TMS (Transcranial Magnetic Stimulation) effectively and non-invasively treats depression without inducing systemic side effects.
Brainsway's technology was cleared by the FDA for treatment of depression patients who did not respond to any number of medication treatments in the current depressive episode. Brainsway's Deep TMS was enthusiastically received by the international academic community, with 60 clinical trials held in major institutions worldwide.
For more information, please visit www.brainsway.com.
Legal Notice Regarding Forward-Looking Statements
This press release contains “forward-looking statements.” Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements."
# # #